💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

Cohen's SAC Capital in $135 million settlement with Elan investors

Published 11/30/2016, 07:23 PM
© Reuters. An exterior view of the headquarters of SAC Capital Advisors, L.P. in Stamford, Connecticut
PFE
-
PRGO
-

By Jonathan Stempel and Nate Raymond

NEW YORK (Reuters) - Billionaire Steven A. Cohen's former hedge fund SAC Capital Advisors LP will pay $135 million to settle a lawsuit by investors in the drugmaker Elan Corp, who said they lost money because of insider trading by one of his portfolio managers.

The preliminary class-action settlement with SAC, now known as Point72 Asset Management LP, was filed on Wednesday with the federal court in Manhattan, and requires approval by U.S. District Judge John Koeltl.

It resolves claims over an estimated $275 million of illegal trading gains in Elan and the drugmaker Wyeth by Mathew Martoma, who worked at SAC's CR Intrinsic Investors unit, based on tips from a Michigan doctor about a 2008 Alzheimer's drug trial.

"We are pleased to have resolved this matter and close the books on this chapter of SAC-era litigation," Point72 spokesman Mark Herr said in a statement.

SAC pleaded guilty to fraud in 2013 and paid $1.8 billion in criminal and civil settlements with U.S. authorities. It settled with Wyeth shareholders for $10 million last December.

Martoma, meanwhile, is appealing his February 2014 insider trading conviction, while he serves a nine-year prison term.

Cohen, 60, was not criminally charged, but in January accepted a two-year ban on managing money for outside investors to end a U.S. Securities and Exchange Commission civil probe into his supervision of Martoma.

That ban ends on Jan. 1, 2018, and no fine was imposed. Point72 is based in Stamford, Connecticut.

SAC and Cohen did not admit wrongdoing in settling with the former Elan investors, including purchasers of its American depositary receipts and stock options.

Perrigo Co (N:PRGO) bought Elan in 2013, while Pfizer Inc (N:PFE) bought Wyeth in 2009.

Lawyers for the Elan investors plan to seek up to $35.1 million for legal fees and $2.8 million for costs, which would be drawn from the $135 million settlement, court papers show.

Cohen can donate leftover settlement funds to charities he chooses, with the consent of the Elan investors. He is worth $13 billion, Forbes magazine said.

© Reuters. An exterior view of the headquarters of SAC Capital Advisors, L.P. in Stamford, Connecticut

The case is Kaplan et al v SAC Capital Advisors LP et al, U.S. District Court, Southern District of New York, No. 12-09350.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.